NW Bio expands cancer drug study

Northwest Biotherapeutics Inc., of Bethesda, which is developing non-toxic personalized immune therapies for solid tumor cancers, said it completed recruiting patients for the first phase of a clinical trial testing the efficacy of a potential cancer drug.

Leave a Reply

Your email address will not be published. Required fields are marked *